

Approved prescription drug products with therapeutic equivalence evaluations.

[Washington, D.C.?] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs : 1980-

<http://hdl.handle.net/2027/mdp.39015072933081>

HathiTrust



www.hathitrust.org

Public Domain, Google-digitized


http://www.hathitrust.org/access_use#pd-google

We have determined this work to be in the public domain, meaning that it is not subject to copyright. Users are free to copy, use, and redistribute the work in part or in whole. It is possible that current copyright holders, heirs or the estate of the authors of individual portions of the work, such as illustrations or photographs, assert copyrights over these portions. Depending on the nature of subsequent use that is made, additional rights may need to be obtained independently of anything we can address. The digital images and OCR of this work were produced by Google, Inc. (indicated by a watermark on each page in the PageTurner). Google requests that the images and OCR not be re-hosted, redistributed or used commercially. The images are provided for educational, scholarly, non-commercial purposes.

Generated for Shearrer, Cynthia D. (University of Missouri - Columbia) on 2018-05-15 12:35 GMT / http://hdl.handle.net/2027/mdp.39015072933061

**CUMULATIVE
SUPPLEMENT 2
AUG '82 - OCT '82**

The University
of Michigan
Pharmacy
Library



**APPROVED
PRESCRIPTION
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

3RD EDITION

REFERENCE
DOES NOT ORIGINATE

PHARMACY
R17
300
3rd ed.
Suppl. 2

SERIAL
REFERENCE

MAN 24 1983
THE UNIVERSITY
OF MICHIGAN
PHARMACY
LIBRARY

UNIVERSITY OF MICHIGAN
LIBRARIES

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

DEC 10 1982

DEPOSITED BY THE
UNITED STATES OF AMERICA

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 3rd Edition, (the List) to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature are identified by the term "List". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the Addendum: DESI Pending List.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1982. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol > add > to the left of the line on which new information exists. The > add > symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLI> (DELETE) to the left of the line containing the overstruck print. The >DLI> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (⌘) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. INDICES AND ABBREVIATIONS:

STANDARD TERMS:

Added Route of Administration: INTRAPERITONEAL

B. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The format of this report was modified this month to include counts of new molecular entities (NME) and salts, esters and derivatives of NME's approved by the agency each month during the past quarter.

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '82. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented, users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in products as either multisource or single source.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '82
DRUG PRODUCTS LISTED	6303
SINGLE SOURCE	1885 (30%)
MULTISOURCE (1)	4418 (70%)
THERAPEUTICALLY EQUIVALENT	3456 (54.8%)
NOT THERAPEUTICALLY EQUIVALENT	954 (15.1%)
EXCEPTIONS (2)	8 (0.1%)
NUMBER OF APPLICANTS	303

B. ACTIVITY FOR SUPPLEMENT NUMBER 2 AND CUMULATIVE SINCE JULY '82

	AUG-SEPT '82	OCT '82	CUMULATIVE
DRUG PRODUCTS ADDED:	85	44	129
NEWLY APPROVED	85	43	128
DESI EFFECTIVE	0	0	0
REMARKETED	0	1	1
DRUG PRODUCTS REMOVED:	18	21	39
WITHDRAWN APPROVAL	0	0	0
RX TO OTC SWITCH	2	0	2
DISCONTINUED MARKETING	16	21	37
NET GAIN IN DRUG PRODUCTS	67	23	90
NEW SINGLE SOURCE PRODUCTS	26	14	40
NEW MULTISOURCE DRUG PRODUCTS	59	30	89
NEWLY APPROVED MOLECULAR ENTITIES:	7	2	9
NEW MOLECULAR ENTITIES (NME'S)	6	2	8
NEW SALTS, ESTERS AND DERIVATIVES	0	0	0
OF PREVIOUSLY APPROVED NME'S	0	0	0

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (1.e., AVAILABLE FROM MORE THAN ONE APPLICANT)
 (2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 2-8 OF THE LIST)

APPROVED PRESCRIPTION DRUG PRODUCTS
 DRUG PRODUCT LIST
 CUMULATIVE SUPPLEMENT NUMBER 2 / AUGUST '82 - OCTOBER '82

1

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

TABLET; ORAL

> DLT > /AA/ ACETAMINOPHEN W/ CODEINE PHOSPHATE
 /CARRICK/60/ CARRICK/325MG;30MG/

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL

TALACEN
 STERLING DRUG 650MG;EQ 25MG BASEM

ACETAZOLAMIDE (PAGE 3-3)

TABLET; ORAL

> ADD > AB ACETAZOLAMIDE
 ASCOT HOSP PHARMS 250MGX

> ADD > ACYCLOVIR SODIUM (PAGE 3-4)

> ADD > INJECTABLE; INJECTION

> ADD > ZOVIRAX
 BURROUGHS WELLCOME EQ 500MG BASE/VIALX

> DLT > /ALUMINUM 'CHLORHYDROXY' ALLANTOINATE; 'PREDNISOLONE' (PAGE 3-5)

> DLT > /CREAM; TOPICAL/
 > DLT > /METI-DERM/
 > DLT > /SCHERING/ 10.25%;0.5%/

> DLT > /ALUMINUM 'NICOTINATE' (PAGE 3-5)

> DLT > /TABLET; ORAL/
 > DLT > /NICALEX/
 > DLT > /HERRELL DON/DON CHEN/625MG/

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION

> ADD > HEPATAMINE 8%
 > ADD > AM MCGAW/AM HOSP 8%
 NOVAMINE 8.5%
 CUTTER LABORATORIES 8.5%
 NOVAMINE 11.4%
 CUTTER LABORATORIES 11.4%
 > ADD > RENAMIN W/O ELECTROLYTES
 > ADD > TRAVENOL LABS 6.5%
 > ADD >

AMINOCAPROIC ACID (PAGE 3-7)

INJECTABLE; INJECTION

> ADD > AMICAR
 LEDERLE PARENTERALS 250MG/ML
 > ADD > AMINOCAPROIC ACID
 > ADD > AP ELKINS-SINN/AHROBINS 250MG/MLX

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE (PAGE 3-11)

CAPSULE; ORAL

DELCOBESE
 /DELCO CHEMICAL/ 1.25MG;1.25MG;1.25MG;1.25MG/
 2.5MG;2.5MG;2.5MG;2.5MG/
 3.75MG;3.75MG;3.75MG;3.75MG/
 5MG;5MG;5MG;5MG/
 LEMMON 1.25MG;1.25MG;1.25MG;1.25MG
 2.5MG;2.5MG;2.5MG;2.5MG
 3.75MG;3.75MG;3.75MG;3.75MG
 5MG;5MG;5MG;5MG

TABLET; ORAL

DELCOBESE
 /DELCO CHEMICAL/ 1.25MG;1.25MG;1.25MG;1.25MG/
 2.5MG;2.5MG;2.5MG;2.5MG/
 3.75MG;3.75MG;3.75MG;3.75MG/
 5MG;5MG;5MG;5MG/
 LEMMON 1.25MG;1.25MG;1.25MG;1.25MG
 2.5MG; 2.5MG;2.5MG;2.5MG
 3.75MG;3.75MG;3.75MG;3.75MG
 5MG;5MG;5MG;5MG

ASPIRIN; CAFFEINE; PHENACETIN; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-15)

CAPSULE; ORAL

/AA/ PROPOXYPHENE HCL COMPOUND 65
 /ROXANE LABORATORIES/227MG;32.4MG;162MG;65MG/

AZLOCILLIN SODIUM (PAGE 3-17)

INJECTABLE; INJECTION

AZLIN
 MILES PHARMS/MILES EQ 2GM BASE/VIALX
 EQ 3GM BASE/VIALX
 EQ 4GM BASE/VIALX

CHLOROTHALIDONE (PAGE 3-37)

TABLET; ORAL
CHLOROTHALIDONE
 > ADD > AB ASCOT HOSP PHARMS 25MGH
 > ADD > AB 50MGH

CHLORZOXAZONE (PAGE 3-37)

TABLET; ORAL
CHLORZOXAZONE
 AA CHELSEA LABORATORIES 250MGH

CYCLOPHOSPHAMIDE (PAGE 3-44)

INJECTABLE; INJECTION
CYTOXAN
 HEAD JOHNSON/B-M 1GM/VIALM
 2GM/VIALM

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-44)

TABLET; ORAL
CYPROHEPTADINE HCL
 > ADD > AA ASCOT HOSP PHARMS 4MGH
 /AA/ /FRENCH PHARM LABS/ /4MG/
 AA LEMMON 4MG

DEXAMETHASONE (PAGE 3-47)

TABLET; ORAL
DEXAMETHASONE
 > DLT > /BP/ /LEPÉRE, LABS/ AM. CYAN/ 0.25MG/
 > DLT > /BP/ /1.5MG/
 ROXANE LABORATORIES 2MGH

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-48)

INJECTABLE; INJECTION
DEXAMETHASONE
 AP ELKINS-SINN/AHROBINS EQ 4MG PHOSPHATE/ML
 AP EQ 10MG PHOSPHATE/MLM
DEXAMETHASONE SODIUM PHOSPHATE
 /AP/ /ELKINS-SINN/AHROBINS/ EQ 4MG PHOSPHATE/ML/

SOLUTION/DROPS; OPHTHALMIC
DEXAMETHASONE SODIUM PHOSPHATE
 > DLT > /AT/ BARNES-HIND PHARMS EQ 0.1% PHOSPHATE
 > DLT > /AT/ /MAURRY BIOLOGICAL/ /EQ 0.1% PHOSPHATE/

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-48)

SOLUTION/DROPS; OPHTHALMIC, OTIC
DECADRON
 > ADD > AT MSD MERCK EQ 0.1% PHOSPHATE
 > ADD > DEXAMETHASONE SODIUM PHOSPHATE
 > ADD > AT MAURRY BIOLOGICAL EQ 0.1% PHOSPHATE

/DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE/ (PAGE 3-49)

/TABLET; ORAL/
 /DISOPHROL/
 /SCHERING/ /2MG;60MG/
 /TABLET; CONTROLLED RELEASE; ORAL/
 /PRIOXAL/
 /SCHERING/ /6MG;120MG/

DIATRIZOATE MEGLUMINE (PAGE 3-54)

INJECTABLE; INJECTION
ANGIOVIST 282
 AP BERLEX/SCHERING AG 60%
UROVIST MEGLUMINE DIU/CT
 AP BERLEX/SCHERING AG 30%

SOLUTION; URETHRAL
UROVIST CYSTO
 AT BERLEX/SCHERING AG 30%
UROVIST CYSTO PEDIATRIC
 AT BERLEX/SCHERING AG 30%

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION
ANGIOVIST 292
 AP BERLEX/SCHERING AG 52%:82%
ANGIOVIST 370
 AP BERLEX/SCHERING AG 66%:102%

SOLUTION; ORAL, RECTAL
GASTROVIST
 AA BERLEX/SCHERING AG 66%:102%

DIATRIZOATE SODIUM (PAGE 3-54)

INJECTABLE; INJECTION
UROVIST SODIUM 300
 AP BERLEX/SCHERING AG 50%

Original from
UNIVERSITY OF MICHIGAN

Digitized by Google

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-63)

INJECTABLE; INJECTION
XYLOCAINE W/ EPINEPHRINE
ASTRA PHARM PRODS 0.005MG/ML;0.5%
0.005MG/ML;0.5%

ERGOLLOID MESYLATES (PAGE 3-63)

TABLET; ORAL
ERGOTOLO MESYLATES
DANBURY PHARMACAL
AB
TNGX

TABLET: SUBLINGUAL	AKERGOT	0.546	0.546	0.546	0.546
PRENO. PHARM. LABS/	LEMON	ADD >	ADD >	ADD >	ADD >
DLT >	DLT >	DLT >	DLT >	DLT >	DLT >

H.E.A.
VANGARD LABS/MMM
0.ENGX
MMMM

ETHINYL ESTRADIOL; ETHINYL DIACETATE; FERDUS FUMARATE/ (PAGE 3-69)

TABLET, ORAL-28/ DENULEN-FE-28/ SEARLE/SEARLE PHARMS/0.05MG;1MG;75MG/	1
---	---

ETOMIDATE (PAGE 3-71)

INJECTABLE; INJECTION
AMIDATE
ABBOTT LABORATORIES 2MG/ML*

FENFLURAMINE HYDROCHLORIDE (PAGE 3-71)

TABLET, CONTROLLED RELEASE; ORAL
PONDIMIN
AH ROBINS
60MG#

FLUOROURACIL (PAGE 3-73)

CARTER-GLOGAU LABS 50MG/MLX > ADD > AP

DIMETHYLDIMETHYLAMINE (PAGE 3-57)

INJECTABLE; INJECTION
DIMETHYLDIMATE
/CENTRAL PHARMS/
/SONG/ML/

/SUPPOSITORY; RECTAL/
/DRAIATINE /
/SEARLE PHARMS/
/100MG/

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-58)

CAPSULE; ORAL	/AA/	<	VANGARD LABS/MWM	25mg/
DIPHENHYDRAMINE HCL	/AA/	<		50mg/
<u>FRENO PHARM LABS/</u>	/AA/	>		25mg/

DOPAMINE HYDROCHLORIDE (PAGE 3-60)

INJECTABLE; INJECTION
DOFAMINE HCL
ABBOTT LABORATORIES
80MG/MLx

DOXYCYCLINE HYCLATE (PAGE 3-61)

ADD	AB	ADD	AB
<	<	<	<
>	>	>	>
CAPSULE; ORAL			
DOXYCYCLINE HYCLATE			
DANBURY PHARMACAL			
EQ 100MG BASE			
EQ 100MG BASE			

TABLET; ORAL
DOXYCYCLINE HYCLATE
BARR LABORATORIES
EQ 100MG BASE

DYDROGESTERONE (PAGE 3-61)

TABLET; ORAL
/pUshastOn/
/pOXANE, TABPORA TORIES/ 5MG/
/1010s/
< DLT > /BP/ GYNOREST
< DLT > /BP/ HEAD JOHNSON/B-M
< DLT > /BP/ 5MG 10MG

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE (PAGE 3-62)

INJECTABLE; INJECTION
/DURANEST, W./ EPINEPHRINE/
DURANEST

GENTAMICIN SULFATE (PAGE 3-76)

INJECTABLE; INJECTION
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER
TRAVENOL LABS EQ 0.8MG BASE/MLM
EQ 80MG BASE/100MLM

GONADORELIN HYDROCHLORIDE (PAGE 3-77)

INJECTABLE; INJECTION
FACTREL
AYERST LABS/AMHO EQ 0.1MG BASE/VIALM
EQ 0.5MG BASE/VIALM

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-77)

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN
AT PHARMAFAIR, 0.025MG/ML; EQ 1.75MG BASE/ML;
AT 5,000 UNITS/MLM
0.025MG/ML; EQ 1.75MG BASE/ML;
10,000 UNITS/MLM

GUANABENZ ACETATE (PAGE 3-78)

TABLET; ORAL
WYTENSIN
WYETH LABS/AMHO EQ 4MG BASEM
EQ 8MG BASEM

HALOPERIDOL (PAGE 3-78)

> DLT > /CONCENTRATES; ORAL/
> DLT > /HALDOL/
> DLT > /MCNEIL LABORATORIES//2MG/ML/

> DLT > /INJECTABLE; INJECTION/
> DLT > /HALDOL/
> DLT > /MCNEIL LABORATORIES//5MG/ML/

> ADD > HALOPERIDOL LACTATE (PAGE 3-79)

> ADD > CONCENTRATE; ORAL
> ADD > HALDOL
> ADD > MCNEIL LABORATORIES EQ 2MG BASE/ML

> ADD > INJECTABLE; INJECTION
> ADD > HALDOL
> ADD > MCNEIL LABORATORIES EQ 5MG BASE/ML

HYALURONIDASE (PAGE 3-82)

INJECTABLE; INJECTION
/ALTOASE/
/AP/ /SEARLE PHARMS/ /150 UNITS/VIAL/
WYDASE
/AP/ /WYETH LABS/AMHO/ /150 UNITS/VIAL/
WYETH LABS/AMHO 150 UNITS/VIAL

HYDRALAZINE HYDROCHLORIDE (PAGE 3-82)

TABLET; ORAL
HYDRALAZINE HCL
> ADD > AA PAR PHARMACEUTICALS 10MGH
/AA/ /PREMO PHARM LABS/ /25MG/
/AA/ /50MG/
AA LEMMON 50MG

HYDROCORTISONE (PAGE 3-85)

LOTION; TOPICAL
NUTRACORT
/AT/ /OWEN LABS/ALCON LABS/0.5%/
/AT/ /1%/
AT OWEN LABS/DERM PRODS 0.5%
AT 1%
2.5%M

ointment; TOPICAL
> ADD > HYMAC
> ADD > AT NMC LABS 1%M

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-88)

SOLUTION; OTIC
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE
AT PHARMAFAIR 1% EQ 3.5MG BASE/ML; 10,000 UNITS/MLM

HYDROCORTISONE BUTYRATE (PAGE 3-89)

> ADD > ointment; TOPICAL
> ADD > LOCID
> ADD > GIST-BROCADES/NETH 0.1%M

HYDROXOCOBALAMIN (PAGE 3-90)

INJECTABLE; INJECTION
> DLT > /ALPHA-EUITE/
> DLT > /AP/ /SAVAGE LABS/BYK-ELON/1MG/ML/

HYDROXYZINE HYDROCHLORIDE (PAGE 3-91)

TABLET; ORAL	HYDROXYZINE HCL	/PREN. PHARM. LABS/	50MG
> DLT > /AB/		LEMON	50MG
> ADD > AB			

HYDROXYZINE PAMATE (PAGE 3-91)

[illegible]

IMIPRAMINE HYDROCHLORIDE (PAGE 3-92)

[illegible]

> DLT > /IDCARMATE HEADLINE (PAGE 3-93)
> DLT > /INJECTABLE; INJECTION/
> DLT > /BINARY/
> DLT > /WALLINGKRODT/
> DLT > /608HS/ML/

IPODATE SODIUM (PAGE 3-95)

AA	500MG	ER SQUIBB AND SONS
AA	500MG	GRAGAFIN SODIUM
AA	500MG	BERLEX/SCHERING AG
AA	500MG	BILIVIST
AA	500MG	CAPSULE; ORAL

LEUCOVORIN CALCIUM (PAGE 3-98)

$$\begin{array}{r} \text{DLT} \\ \hline \text{DLT} \\ \hline \text{ADD} \\ \hline \text{ADD} \\ \hline \text{ADD} \\ \hline \text{ADD} \\ \hline \text{ADD} \\ \hline \text{ADD} \end{array}$$

JECTABLE; INJECTION
LEUCOVORIN CALCIUM
LEDERLE LABS/AM CYAN/5MG/ML
/50MG/VIAL/
EQ 3MG BASE/ML
EQ 50MG BASE/VIAL
WELLCOVORIN
BURROUGHS WELLCOME
EQ 5MG BASE/MLX

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE (PAGE 3-103)

SOLUTION; IRRIGATION

PHYSOSOL IN PLASTIC CONTAINER

LABORATORIES//14MG/100ML; 3.7MG/100ML; 2.2MG/100ML; //

LABORATORIES 30MG/100ML; 5.7MG/100ML; 2.2MG/100ML; 5.2MG/100ML

MALATHION (PAGE 3-104)

LOTION; TOPICAL
PRIDERM
PURDUE FREDERICK
0.5%

MAPROTILINE HYDROCHLORIDE (PAGE 3-104)

TABLET; ORAL
LUDIONMIL
CIBA/CIBA-GEIGY
> ADD >
75MGX

MEPIVACAINA HYDROCHLORIDE (PAGE 3-107)

INJECTABLE; INJECTION	12	12
<u>CARDONATE</u>		
BACON LABS/STERLING	12	
<u>MEFIVACINE HCL</u>		
INTL MEDICATION SYS	12	

MEPROBAMATE (PAGE 3-107)

TABLET; ORAL
MEFENAMATE
> DLT > /AA/ / FEPERLE TABS/AM CYAN/200MG/

METHADONE HYDROCHLORIDE (PAGE 3-110)

SOLUTION; ORAL
METHADONE HCL
ROXANE LABORATORIES
10MG/5MLx

METHANTHELINE BROMIDE (PAGE 3-111)

~~/INJECTABLE; INJECTION/~~
~~/BANTHINE/~~
~~/SEARLE/SEARLE PHARMS/50MG/VIAL/~~

METHOCARBAMOL (PAGE 3-112)

TABLET; ORAL
METHOCARBAMOL

> ADD > AA ASCOT HOSP. PHARMS 500MGX
> ADD > AA 750MGX

METHYCLOTHIAZIDE (PAGE 3-114)

TABLET; ORAL
METHYCLOTHIAZIDE

AB MYLAN PHARMS 2.5MGX
AB 5MGX

METHYLPREDNISOLONE ACETATE (PAGE 3-115)

INJECTABLE; INJECTION
METHYLPREDNISOLONE ACETATE

> ADD > BP MAURRY BIOLOGICAL 40MG/MLX
> ADD > BP 80MG/MLX

METRONIDAZOLE (PAGE 3-117)

INJECTABLE; INJECTION
METRO I.V.

AP AM MCGAW/AM HOSP 500MG/100MLX

TABLET; ORAL
METRONIDAZOLE

> ADD > AB CHELSEA LABORATORIES 250MGX
> ADD > AB CORD LABORATORIES 250MGX
> ADD > AB 500MGX
> ADD > AB DANBURY PHARMACAL 250MGX
/AB/ /LEMMON/ /250MG/
METRYL
AB LENNON 250MG

MINOCYCLINE HYDROCHLORIDE (PAGE 3-118)

TABLET; ORAL
MINOCIN

LEDERLE LABS/AM CYAN EQ 50MG BASEX
EQ 100MG BASEX

NYSTATIN (PAGE 3-123)

ointment; TOPICAL
NYSTATIN

AT BYK-GULDEN 100,000 UNITS/GMX

> DLT > /oxolinic Acid/ (PAGE 3-125)

> DLT > /TABLET; ORAL/
> DLT > /OTIBID/
> DLT > /PARKE-DAVIS/A-L/ /750MG/

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-126)

CAPSULE; ORAL
OXYTETRACYCLINE HCL

/AB/ /LEDERLE LABS/AM CYAN/EQ 250MG BASE/

PHENDIMETRAZINE TARTRATE (PAGE 3-132)

CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE

/AA/ /CORD LABORATORIES/ /35MG/
AA REID-PROVIDENT LABS 35MG
X-TROZINE
AA REXAR PHARMACAL 35MGX

CAPSULE, CONTROLLED RELEASE; ORAL

> ADD > MELFIAT-105
> ADD > BC REID-PROVIDENT LABS 105MGX
X-TROZINE L.A.
BC REXAR PHARMACAL 105MGX

PHENTERMINE HYDROCHLORIDE (PAGE 3-133)

TABLET; ORAL
PHENTERMINE HCL

/AA/ /CORD LABORATORIES/ /8MG/
TCRA
AA REID-PROVIDENT LABS 8MG

PINDOLOL (PAGE 3-135)

TABLET; ORAL
VISKEN

SANDOZ PHARMS/SANDOZ 5MGX
10MGX
15MGX

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 2 / AUGUST '82 - OCTOBER '82

8

PROPPOXYPHENE HYDROCHLORIDE (PAGE 3-147)

CAPSULE; ORAL
/AA/ /PREMO PHARM LABS/ /65MG/
/AA/ LEMMON
/AA/ /ROXYANE LABORATORIES/ /65MG/

PYRIDOXINE HYDROCHLORIDE (PAGE 3-149)

INJECTABLE; INJECTION
PYRIDOXINE HCL
/ADD > AP MAURRY BIOLOGICAL 100MG/MLX

QUINIDINE GLUCONATE (PAGE 3-150)

TABLET, CONTROLLED RELEASE; ORAL
QUINIDINE GLUCONATE
/AB DANBURY PHARMACAL 324MGX

> DLT > /SISDICHIN SULFATE/ (PAGE 3-155)

> DLT > /INJECTABLE; INJECTION/
> DLT > /SISSEPTIN/
> DLT > /SCHEERIN6/

SODIUM CHLORIDE (PAGE 3-155)

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
> ADD > ABBOTT LABORATORIES 9MG/MLX
> ADD > ABBOTT LABORATORIES 9MG/MLX
> ADD > AP SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

SPIRONOLACTONE (PAGE 3-159)

TABLET; ORAL
SPIRONOLACTONE
> ADD > AB ASCOT HOSP PHARMS 25MGX

SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE; UREA (PAGE 3-160)

CREAM; VAGINAL

SULNAG

AT NMC LABORATORIES

3.77%2.86%3.42%0.64%2X

> DLT > /SULFAMETER/ (PAGE 3-161)

/TABLET; ORAL/

/SULLA/

/BERLEX/SCHERING/

/500MG/

PREDNISOLONE (PAGE 3-139)

> ADD > CREAM; TOPICAL
> ADD > METI-DERM
> ADD > SCHERING 0.5%

TABLET; ORAL

PREDNISOLONE

/BX/ /PUPREPAC/KALIPHARMA/ /5MG/

PROBENECID (PAGE 3-142)

TABLET; ORAL

PROBENECID

/AB/ /BEECHAM LABS/BEECHAM/ 500MG/

PROCHLORPERAZINE EDISYLATE (PAGE 3-144)

INJECTABLE; INJECTION

> ADD > /AB ELKINS-SINN/AHROBINS EQ 5MG BASE/MLX

SYRUP; ORAL

COMPAZINE

/AA SK&F LABORATORIES EQ 5MG BASE/MLX

/AA PROCHLORPERAZINE EDISYLATE

/AA NATL PHARM MFG/BARRE EQ 5MG BASE/MLX

PROMETHAZINE HYDROCHLORIDE (PAGE 3-145)

INJECTABLE; INJECTION

/PHEN-50/

/CENTRAL PHARMS/

/50MG/ML/

TABLET; ORAL

PROMETHAZINE HCL

> DLT > /BP/ /LEDERLE LABS/AM CYAN/25MG/
> DLT > /BP/ /50MG/

PROPANTHELINE BROMIDE (PAGE 3-146)

TABLET; ORAL

PROPANTHELINE BROMIDE

> ADD > AA ASCOT HOSP PHARMS 15MGX

PROPACACINE HYDROCHLORIDE (PAGE 3-146)

SOLUTION/DROPS; OPHTHALMIC

PARACACINE

AT PRO PHARMA/STERI-MED 0.5%2X

SULFAMETHOXAZOLE (PAGE 3-161)

TABLET; ORAL

SULFAMETHOXAZOLE

> ADD > AB ASCOT HOSP PHARMS 500MG

SULFINPYRAZONE (PAGE 3-162)

CAPSULE; ORAL

ANTURANE

AB CIBA/CIBA-GEIGY 200MG

SULFINPYRAZONE

AB BARR LABORATORIES 200MG

TABLET; ORAL

SULFINPYRAZONE

AB BARR LABORATORIES 100MG

SULFISOXAZOLE (PAGE 3-162)

TABLET; ORAL

SULFISOXAZOLE

> DLT > /BP/ /PREMO PHARM LABS/ /500MG/

> ADD > BP LEMMON 500MG

TECHNETIUM, TC-99M, MEDRONATE KIT (PAGE 3-164)

INJECTABLE; INJECTION

AMERSCAN

AP AMERSHAM/RADIOCHEM N/A

TECHNETIUM, TC-99M, SULFUR COLLOID (PAGE 3-165)

INJECTABLE; INJECTION

TECHNETIUM TC 99M SULFUR COLLOID

/SYNCO. INTL/ /2mCi/mL/

THEOPHYLLINE (PAGE 3-168)

SYRUP; ORAL

SLO-PHYLLIN-80

/AA/ /BOONER LABORATORIES/ /80MG/15ML/

SLO-PHYLLIN

AA WILLIAM H RORER 80MG/15ML

TABLET; ORAL

SLO-PHYLLIN

/BP/ /BOONER LABORATORIES/ /100MG/

/BP/ /BOONER LABORATORIES/ /200MG/

BD WILLIAM H RORER 100MG

BD WILLIAM H RORER 200MG

THEOPHYLLINE (PAGE 3-168)

TABLET, CONTROLLED RELEASE; ORAL

THEOCONTIN

PURDUE FREDERICK 400MG

THIAMINE HYDROCHLORIDE (PAGE 3-169)

INJECTABLE; INJECTION

THIAMINE HCL

> ADD > AP MAURRY BIOLOGICAL 100MG/ML

TRIAMCINOLONE ACETONIDE (PAGE 3-173)

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT PHARMAFAIR 0.025%

AT 0.1%

AT 0.5%

LOTION; TOPICAL

KENALOG

AT ER SQUIBB AND SONS 0.025%

AT 0.1%

TRIAMCINOLONE ACETONIDE

AT NATL PHARM MFG/BARRE 0.025%

AT 0.1%

TRICHLORMETHIAZIDE (PAGE 3-174)

TABLET; ORAL

TRICHLORMETHIAZIDE

> DLT > /BP/ /PREMO PHARM LABS/ /4MG/

> ADD > BP LEMMON 4MG

TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-175)

CONCENTRATE; ORAL

TRIFLUOPERAZINE

TFP

TRIMETHOBENZAMIDE HYDROCHLORIDE (PAGE 3-176)

INJECTABLE; INJECTION

TIGAN

> ADD > AP BEECHAM LABS/BEECHAM 100MG/ML

> ADD > AP TRIMETHOBENZAMIDE HCL

> ADD > AP CARTER-GLOGAU LABS 100MG/ML

TRIMIPRAMINE MALEATE (PAGE 3-176)

CAPSULE; ORAL
SURMONTIL
IVES LABS/AMHO
EQ 100MG BASEM

TROPICAMIDE (PAGE 3-178)

SOLUTION/DROPS; OPHTHALMIC
HYDRACLYL
ALCON LABORATORIES 1Z
TROPICAMIDE
PRO PHARMA/STERI-MED 1Z

VITAMIN A (PAGE 3-179)

CAPSULE; ORAL
VITAMIN A
LEPERLE LABS/AM CYAN/50,000 IU
> DLT./>/AA/

WARFARIN SODIUM (PAGE 3-180)

TABLET; ORAL
ATHROMBIN
PURDUE, FREDERICK/
BP/ BP/ 5MG/
BP/ BP/ 10MG/
BP/ BP/ 5MG
BX
COUNADIN
ENDO LABS/DUPONT/
BP/ BP/ 2MG/
BP/ BP/ 2.5MG/
BP/ BP/ 5MG/
BP/ BP/ 7.5MG/
BP/ BP/ 10MG/
BX
ENDO LABS/DUPONT
BX
BX
BX
BX
BX
10MG

WARFARIN SODIUM (PAGE 3-180)

TABLET; ORAL
PANMARFIN
BP/ BP/ 2MG/
BP/ BP/ 2.5MG/
BP/ BP/ 5MG/
BP/ BP/ 7.5MG/
BP/ BP/ 10MG/
BX
ABBOTT LABORATORIES
2MG
BX
2.5MG
BX
5MG
BX
7.5MG
BX
10MG
BX
WARFARIN SODIUM
BOLAR PHARMACEUTICAL 2MG
BX
2.5MG
BX
5MG
BX
7.5MG
BX
10MG
BX

WATER FOR INJECTION, STERILE (PAGE 3-180)

LIQUID; N/A
BACTERIOSTATIC WATER IN PLASTIC CONTAINER
ABBOTT LABORATORIES 100%
> ADD >
> ADD >

XENON, XE-127 (PAGE 3-181)

> ADD >
> ADD >
> ADD >
> ADD >
GAS; INHALATION
XENON XE 127
MALLINCKRODT
> ADD >
SMCI/VIALM
10MCI/VIALM

ADDENDUM
DESI PENDING LIST
CUMULATIVE SUPPLEMENT NUMBER 2 / AUGUST '82 - OCTOBER '82

11

CURRENT STATUS - INEFFECTIVE

> DLT > /BETADINE/ /PURDUE, FREDERICK/
> DLT > /POVIDONE-IODINE/

> DLT > DIPYRIDAMOLE /FREED, PHARM, LABS/
> ADD > LEMMON

CURRENT STATUS - 'EXEMPT' (COURT ORDER)

> DLT > BUTIBEL /MCNEIL, LABORATORIES/
> ADD > WALLACE LABS/C-W

> ADD > DIPYRIDAMOLE ASCOT HOSP PHARMS
> ADD > DIPYRIDAMOLE

> ADD > DIPYRIDAMOLE HALSEY DRUG
> ADD > DIPYRIDAMOLE

DIPYRIDAMOLE SUPERPHARM
DIPYRIDAMOLE

> ADD > HYBEPHEN BEECHAM LABS/BEECHAM
> ADD > ATROPINE SULFATE; HYOSCYAMINE SULFATE; PHENOBARBITAL;
> ADD > SCOPOLAMINE HYDROBROMIDE


ISOSORBIDE DINITRATE INWOOD LABS/FOREST
ISOSORBIDE DINITRATE

METHANDROSTENOLONE PAR PHARMACEUTICAL
METHANDROSTENOLONE

> ADD > NITRO-TIME TIME-CAP LABS
> ADD > NITROGLYCERIN

NITROGLYCERIN VITARINE/WEST CHEM
NITROGLYCERIN

NITROSTAT PARKE-DAVIS/W-L
NITROGLYCERIN



Digitized by 

Original from
UNIVERSITY OF MICHIGAN

